Clive Richardson Net Worth

Mr. Clive Richardson biography

Clive Richardson is the COO, CEO & Director at Akari Therapeutics Plc.

What is the salary of Mr Richardson?

As the COO and CEO & Director of Akari Therapeutics Plc, the total compensation of Mr Richardson at Akari Therapeutics Plc is $780,943. There are no executives at Akari Therapeutics Plc getting paid more.

How old is Mr Richardson?

Mr Richardson is 56, he's been the COO and CEO & Director of Akari Therapeutics Plc since . There are 4 older and 1 younger executives at Akari Therapeutics Plc. The oldest executive at Akari Therapeutics Plc is Dr. Ray Prudo-Chlebosz M.D., 76, who is the Exec. Chairman.

What's Mr Richardson's mailing address?

Clive's mailing address filed with the SEC is C/O LANDMARK FIDUCIAIRE (SUISSE) SA, 6 PLACE DES EAUX-VIVES, PO BOX 3461, GENEVA, V8, 1211.

Insiders trading at Akari Therapeutics Plc

Over the last 9 years, insiders at Akari Therapeutics Plc have traded over $0 worth of Akari Therapeutics Plc stock and bought 1,055,600 units worth $200,564 . The most active insiders traders include Mark S Cohen, Wendy F Dicicco, and Dov Elefant. On average, Akari Therapeutics Plc executives and independent directors trade stock every 0 days with the average trade being worth of $3,693,439. The most recent stock trade was executed by Mark S Cohen on 18 September 2015, trading 1,055,600 units of AKTX stock currently worth $200,564.

What does Akari Therapeutics Plc do?

akari is a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutics to treat orphan autoimmune and inflammatory diseases. akari’s lead drug, coversin, a second-generation and potentially best-in-class complement inhibitor, acts on complement component-c5, preventing release of c5a and formation of c5b – 9 (also known as the membrane attack complex or mac). coversin is a recombinant small protein (16,740 da) derived from a native protein discovered in the saliva of the ornithodoros moubata tick, where it modulates the host immune system to allow the parasite to feed without alerting the host to its presence or provoking an immune response.

Akari Therapeutics Plc executives and stock owners

Akari Therapeutics Plc executives and other stock owners filed with the SEC include:

• Clive Richardson,
  COO, CEO & Director
• Dr. Ray Prudo-Chlebosz M.D.,
  Exec. Chairman
• Dr. Torsten Hombeck,
  Chief Financial Officer
• Stuart Ungar,
  Non-Executive Director
• James Hill,
  Non-Executive Director
• Donald Williams,
  Director
• Robert Ward,
  Director
• Michael Grissinger,
  Director
• Peter Feldschreiber,
  Director
• David Byrne,
  Director
• Nigel Hernandez,
  Vice President - Worldwide Regulatory Affairs
• Clive Richardson,
  Chief Operating Officer, Director
• Torsten Hombeck,
  Chief Financial Officer
• David Solomon,
  Chief Executive Officer
• Ray Prudo,
  Chairman of the Board
• Annie Mack,
  Financial Controller
• Dr. Miles Nunn,
  Chief Scientific Officer
• Dov Elefant,
  Chief Financial Officer
• Allan Shaw,
  Director
• Gur Roshwalb,
  Chief Executive Officer
• Mark S Cohen,
  Director
• Robert M Shaw,
  General Counsel and Secretary
• Samir Rashmikant Patel,
  
• Donald A Williams,
  
• Mohamed Wa'el Ahmed Hashad,
  
• Wendy F Dicicco,
  Interim CFO
• Rachelle Suzanne Jacques,
  Chief Executive Officer